PhenomeX Future Growth
Future criteria checks 2/6
PhenomeX is forecast to grow earnings and revenue by 38.2% and 23.4% per annum respectively. EPS is expected to grow by 53.7% per annum. Return on equity is forecast to be -21.6% in 3 years.
Key information
38.2%
Earnings growth rate
53.7%
EPS growth rate
Life Sciences earnings growth | 16.7% |
Revenue growth rate | 23.4% |
Future return on equity | -21.6% |
Analyst coverage | Good |
Last updated | 05 Sep 2023 |
Recent future growth updates
Recent updates
Analyst Forecasts Just Became More Bearish On PhenomeX Inc. (NASDAQ:CELL)
May 16PhenomeX Inc.'s (NASDAQ:CELL) Subdued P/S Might Signal An Opportunity
Apr 17Analysts Just Made A Major Revision To Their Berkeley Lights, Inc. (NASDAQ:BLI) Revenue Forecasts
Aug 15Mehul Joshi joins Berkeley Lights as CFO
Jul 25Berkeley Lights Grows Revenue But Operating Losses Mount
Dec 09Are Investors Undervaluing Berkeley Lights, Inc. (NASDAQ:BLI) By 49%?
Nov 07Berkeley Lights: Short Seller Report Raises A Few Legitimate Questions
Sep 23Berkeley Lights: Optofluidic Technology Presents Strong Upside, May Redefine Therapeutic Development
Jun 09Berkeley Lights Q1 2021 Earnings Preview
May 10Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 133 | -47 | -42 | -34 | 5 |
12/31/2024 | 102 | -64 | -51 | -45 | 6 |
12/31/2023 | 76 | -106 | -60 | -54 | 6 |
6/30/2023 | 72 | -125 | -68 | -66 | N/A |
3/31/2023 | 77 | -100 | -61 | -57 | N/A |
12/31/2022 | 79 | -98 | -56 | -48 | N/A |
9/30/2022 | 84 | -86 | -65 | -52 | N/A |
6/30/2022 | 87 | -85 | -68 | -50 | N/A |
3/31/2022 | 87 | -78 | -72 | -52 | N/A |
12/31/2021 | 85 | -72 | -69 | -53 | N/A |
9/30/2021 | 84 | -66 | -54 | -42 | N/A |
6/30/2021 | 78 | -54 | -45 | -39 | N/A |
3/31/2021 | 69 | -50 | -40 | -37 | N/A |
12/31/2020 | 64 | -43 | -39 | -36 | N/A |
9/30/2020 | 59 | -35 | -33 | -30 | N/A |
6/30/2020 | 57 | -32 | -31 | -26 | N/A |
3/31/2020 | 58 | -26 | -27 | -19 | N/A |
12/31/2019 | 57 | -21 | -19 | -11 | N/A |
12/31/2018 | 31 | -27 | -21 | -14 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: CELL is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: CELL is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: CELL is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: CELL's revenue (23.4% per year) is forecast to grow faster than the US market (8.1% per year).
High Growth Revenue: CELL's revenue (23.4% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: CELL is forecast to be unprofitable in 3 years.